XML 155 R28.htm IDEA: XBRL DOCUMENT v3.25.3
Summary of Significant Accounting Policies (Tables)
 9 Months Ended 12 Months Ended
Sep. 30, 2025
Dec. 31, 2024
Summary of Significant Accounting Policies [Abstract]    
Schedule of Diluted Net Loss Per Share

The following table presents the potentially dilutive shares that were excluded from the computation of diluted net loss per share, because their effect was anti-dilutive:

 

   September 30, 
   2025   2024 
Convertible Preferred Stock   
-
    662,921 
Warrants   990,000    4,159 
Stock options   222,635    345,164 
Unvested restricted stock units   16,667    1,292 
Total   1,229,302    1,013,536 

The following table presents the potentially dilutive shares that were excluded from the computation of diluted net loss per share of common stock attributable to common stockholders, because their effect was anti-dilutive:

 

   December 31, 
   2024   2023 
Convertible Preferred Stock   
-
    324,184 
Warrants   961,667    2,034 
Stock options   329,395    369,092 
Convertible Notes   58,824    
-
 
Unvested restricted stock units   739    1,528 
Total   1,350,625    696,838 
Schedule of Consolidated Statements of Cash Flows   The following tables reconcile cash and restricted cash to amounts shown in the consolidated statements of cash flows:
   December 31, 
   2024   2023 
Cash  $2,850   $723 
Restricted cash   142    138 
Total cash and restricted cash  $2,992   $861 
Schedule of Depreciation on Property and Equipment Estimated Useful Lives  

Depreciation on property and equipment is calculated using the straight-line method over the estimated useful lives as follows: 

 

Classification   Estimated
Useful Life
(in years)
Computer hardware and software   3 - 5 
Lab equipment   3 - 5
Furniture and fixtures   5 - 7
Leasehold improvements   Shorter of useful life or lease term
Schedule of Balance Sheet  

The impact of the revision on the Company’s balance sheet as of December 31, 2023 is reflected in the following table:

 

   As previously
reported		   Adjustment   As restated 
Accrued expenses  $2,081   $3,300   $5,381 
Total liabilities   12,891    3,300    16,191 
Accumulated deficit   (105,571)   (3,300)   (108,871)
Total stockholders’ deficit   (85,135)   (3,300)   (88,435)

 

The impact of the revision on the Company’s balance sheet as of December 31, 2022 is reflected in the following table:

 

   As previously
reported		   Adjustment   As restated 
Accrued expenses  $1,897   $3,300   $5,197 
Total liabilities   11,987    3,300    15,287 
Accumulated deficit   (93,865)   (3,300)   (97,165)
Total stockholders’ deficit   (75,734)   (3,300)   (79,034)

 

The impact of the revision on the Company’s balance sheet as of September 30, 2024 is reflected in the following table:

 

   As previously
reported		   Adjustment   As restated 
Accrued expenses  $2,745   $3,300   $6,045 
Total liabilities   15,277    3,300    18,577 
Accumulated deficit   (109,468)   (3,300)   (112,768)
Total stockholders’ deficit   (87,501)   (3,300)   (90,801)